DSS's Role in Evaluating the Diagnosis and Treatment System of Ischemic Cardiovascular and Cerebrovascular Diseases

August 25, 2021 updated by: First Affiliated Hospital Xi'an Jiaotong University

The Research on DSS in Evaluating the Diagnosis and Treatment System of Acute Ischemic Cardiovascular and Cerebrovascular Diseases

Background: Acute ischemic cardiovascular and cerebrovascular diseases are a kind of diseases with high incidence, rapid progression, poor prognosis and high mortality and disability rate of the circulatory system, mainly including acute myocardial infarction, acute ischemic stroke and acute limb ischemia, which place a heavy burden on individuals, families and society due to their severe prognosis and high medical costs. At present, the diagnosis and treatment of ischemic cardiovascular and cerebrovascular diseases mainly focus on single organ diagnosis and treatment of target organs, lacking of indicators to comprehensively evaluate the body's pathophysiology. As ischemic disease of the circulatory system, ischemic cardiovascular and cerebrovascular diseases have common pathophysiological basis such as ischemia, hypoxia and inflammation. These common pathophysiological basis suggests that different acute ischemic cardiovascular and cerebrovascular diseases can be monitored and evaluated from an integrated perspective, it suggests the possibility of comprehensive diagnosis, evaluation and treatment guidance. At present, the "circulatory integration" therapy represented by the combined treatment of heart and brain has achieved certain results, but there is no corresponding evaluation system to provide accurate guidance. Therefore, with the concept of "circulation integration", it is an urgent problem to find the common indicators of the circulation system and construct the hierarchical diagnosis and subsequent evaluation system of acute cardiovascular and cerebrovascular integration. The development of efficient and comprehensive stratified diagnosis and prognosis evaluation system is of great significance in clinical, market and social aspects.

At the early stage of the efforts our team, it was found that Dan Shen Su-(±)-3, 4-dihydroxyphenylacetic acid (DSS) could be detected in the plasma and urine of patients with acute myocardial infarction and ischemic stroke through metabolomics. It has been proved that it can be generated by the transformation of dihydroxyphenylalanine by proteus mirabilis, and its structure is consistent with the water-soluble component of salvia miltiorrhiza, which is related to the body's states of ischemia, hypoxia and inflammation. The findings provide a material basis for the "circulatory integration" assessment of acute ischemic cardiovascular and cerebrovascular diseases.

Objectives: This study aims at acute ischemic cardiovascular and cerebrovascular diseases, with the concept of "circulatory integration", to build a hierarchical diagnosis and prognosis evaluation system with DSS as the core, in order to improve the diagnosis rate and cure rate, improve the prognosis and reduce mortality of ischemic cardiovascular diseases.

Methods: The project included 500 patients with acute myocardial infarction, 300 patients with acute ischemic stroke, 300 patients with acute lower limb ischemia, and 200 healthy controls in the Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, Peoples R China. Plasma and urine were collected during the disease process. Various relevant clinical indicators including DSS level were included, COX model was applied to analyze the influence of multiple factors on the prognosis of the above diseases, and the indicators were screened and the integrated stratified diagnosis and prognosis evaluation system of acute ischemic cardio-cerebrovascular system with DSS as the core were established. The newly established integrated stratified diagnosis and prognosis assessment system was used to evaluate 200 patients with each of the three diseases, and the sensitivity and specificity of the new assessment system were tested. And a simple, rapid and accurate method for detecting DSS was developed.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The experiments as follows:

Experiment 1. Observe the dynamic changes of DSS level in acute ischemic cardiovascular and cerebrovascular diseases of different severity.

  1. Research object Acute myocardial infarction (AMI) group: 500 patients with AMI; Acute ischemic stroke group: 300 patients with acute ischemic stroke; Acute lower limb ischemia group: 300 subjects with acute lower limb ischemia; Control group: 200 healthy volunteers were included as controls. All the subjects were from the first and second affiliated hospitals of the Xi'an Jiaotong University and the Shaanxi Provincial People's Hospital;
  2. Collecting indicators Peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection. The investigators collected several demographics, clinical and analytical parameters. Age, gender, height and weight were recorded, and body mass index (kg/m2) was calculated. Blood pressure (BP) was measured three times or more by a nurse while patients were seated after 5 min of rest. Several parameters, including myocardial enzyme, serum uric acid, total cholesterol, total triglycerides low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, estimated glomerular filtration rate and high sensitivity C-reactive protein were measured. The patient was included in all the clinical data after admission and as the admission diagnosis, including: medical history (including risk factors), physical examination, laboratory examination, imaging examination, nursing report, records of interventional operation and all the indicators of in-hospital examination.
  3. Analyze the regularity curve of DSS level in disease DSS levels of blood and urine were detected by gas chromatography -mass spectrometry (GC-MS). In the disease progression of patients with AMI, acute ischemic stroke and acute lower limb ischemia, the difference of DSS production was analyzed, and the regular curve of the dynamic change process of ischemic cardiovascular and cerebrovascular diseases was plotted based on the normal control group.

Experiment 2. To establish an assessment system of "circulatory integration" for acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core.

  1. The Clinical outcomes on follow up Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The time of recurrence, complication or death, type of complication and cause of death were recorded in detail.
  2. Establish a diagnosis and treatment evaluation system Blood and urine DSS levels were measured by GC-MS. COX regression model analysis, including DSS level, basic information, risk factors, symptoms, physical examination, laboratory tests, image examination and electrocardiogram, assess the influence of various factors on major adverse events in patients with acute ischemic cardiovascular and cerebrovascular diseases and the prognosis of three diseases. Moreover, these indicators were used to build a scoring system, and analyze its correlation with prognosis.

Experiment 3. To verify the "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core

  1. Research Object AMI group: 200 patients with AMI; Acute ischemic stroke group: 200 patients with acute ischemic stroke; Acute lower limb ischemia group: 200 subjects with acute lower limb ischemia; All these subjects were from the first and second affiliated hospitals of the Xi'an Jiaotong University and the Shaanxi Provincial People's Hospital;
  2. Collecting Indicators Peripheral blood and morning urine were collected and measured.
  3. Follow up and record the outcome The major adverse events were observed and recorded in the same way as in the above-mentioned experiment.
  4. Verify the diagnosis and treatment evaluation system The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core was used to predict the prognosis of the newly included 600 patients with acute ischemic cardiovascular and cerebrovascular diseases. This paper analyzes the specificity and sensitivity of the newly built "circular integration" diagnosis and treatment evaluation system through its disease evaluation and actual adverse events.

Study Type

Observational

Enrollment (Anticipated)

1900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Xiaopu Zheng, MD
  • Phone Number: 0086-029-85323818
  • Email: gaokenkx@163.com

Study Contact Backup

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Recruiting
        • First Affiliated Hospital Xi'an Jiaotong University
        • Contact:
      • Xi'an, Shaanxi, China, 710000
        • Not yet recruiting
        • Shaanxi provincial people's hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The project included patients with acute myocardial infarction, patients with acute ischemic stroke, patients with acute lower limb ischemia and 200 healthy controls in the Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, Peoples R China. The study was approved by both Research and Ethics Committees of the First Affiliated Hospital of Xi'an JiaoTong University.

Description

Inclusion Criteria:

  • AMI patients:

    • Patients with age between 18 to 75.
    • Patients with acute ST-segment elevation myocardial infarction less than 12 hours.
    • Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

  • Acute ischemic stroke patients:

    • Patients with age between 18 to 75.
    • Patients with acute ischemic stroke less than 12 hours.
    • National institutes of health stroke scale (NIHSS) scores ranged from 4 to 20.
    • Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

  • Acute lower limb ischemia patients:

    • Patients with age between 18 to 75.
    • Patients with typical " 6P " symptom within 14 days: pain, pulselessness, pallor, paresthesia, paralysis and poikilothermia.
    • The magnetic resonance imaging and ultrasonography of the lower extremity artery showed that there was ischemia in the lower extremity.
    • Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

Exclusion Criteria:

  • • Patients with history of cardiogenic shock or cardiopulmonary resuscitation.

    • Woman during pregnancy or lactation or anyone with mental disorder.
    • A self-identified history of stroke, renal failure, severe arrhythmia or malignant tumor.
    • Previous coronary artery bypass graft surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Acute myocardial infarction (AMI) group
700 patients with AMI;several demographics, clinical and analytical parameters were collected, and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cardiovascular disease of different severity. Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute ischemic cardiovascular diseases.
Acute ischemic stroke group
500 patients with acute ischemic; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in acute ischemic cerebrovascular disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases.
Acute lower limb ischemia group
500 patients with acute lower limb ischemia; several demographics, clinical and analytical parameters were collected,and peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection.Observe the dynamic changes of DSS level in lower limb ischemia disease of different severity.Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The newly established "circulatory integration" diagnosis and treatment evaluation system of lower limb ischemia disease with DSS as the core was used to predict the prognosis of patients with acute cerebrovascular diseases.
Control group
200 healthy volunteers were included as controls

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of disease recurrence
Time Frame: 12 months after admission
Incidence of disease recurrence，including acute myocardial infarction, ischemic stroke and acute lower limb ischemia.
12 months after admission
Incidence of cardiac death
Time Frame: 12 months after admission
All deaths were considered to have been from cardiac causes unless a explicit noncardiac cause could be documented.
12 months after admission
Incidence of all-cause death
Time Frame: 12 months after admission
All deaths were taken into account unless there is a definite cause of accidental death.
12 months after admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

Shaanxi Provincial People's Hospital
Second Affiliated Hospital of Xi'an Jiaotong University

Investigators

  • Principal Investigator: Xiaopu Zheng, MD, First Affiliated Hospital Xi'an Jiaotong University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 22, 2020

Primary Completion (ANTICIPATED)

December 31, 2021

Study Completion (ANTICIPATED)

December 31, 2021

Study Registration Dates

First Submitted

April 21, 2020

First Submitted That Met QC Criteria

April 22, 2020

First Posted (ACTUAL)

April 24, 2020

Study Record Updates

Last Update Posted (ACTUAL)

August 26, 2021

Last Update Submitted That Met QC Criteria

August 25, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019ZDLSF01-01-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myocardial Infarction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe